Related Experiment Video
Updated: Apr 27, 2026
Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
Published on: October 13, 2023
Interferon β-secreting mesenchymal stem cells combined with minocycline attenuate experimental autoimmune
Yun Hou1, Chung Heon Ryu2, Jin Ae Jun1
1Department of Biomedical Science, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Abstract:
We previously demonstrated that interferon β (IFN-β)-secreting mesenchymal stem cells (MSCs-IFN-β) strongly reduced the clinical severity of experimental autoimmune encephalomyelitis (EAE), compared with MSCs alone. Recently, minocycline ameliorates the clinical severity of multiple sclerosis (MS). Herein, we evaluated the effects of a combined treatment of MSCs-IFN-β and minocycline on EAE mice. The combined treatment significantly alleviated the clinical severity mainly by maintaining the integrity of blood-spinal cord barrier, in a manner likely involving inhibition of microvascular disruption, matrix metalloproteinases, neuroinflammation, and enhancement of immunomodulatory effects. Therefore, this combined treatment has the potential to improve the functional recovery of patients with MS.
Insights
Combining interferon β-secreting mesenchymal stem cells (MSCs-IFN-β) with minocycline significantly reduces experimental autoimmune encephalomyelitis (EAE) severity. This approach shows promise for improving functional recovery in multiple sclerosis (MS) patients.
Area of Science:
- Neuroimmunology
- Regenerative Medicine
- Pharmacology
Background:
- Interferon β-secreting mesenchymal stem cells (MSCs-IFN-β) effectively reduce experimental autoimmune encephalomyelitis (EAE) severity.
- Minocycline is known to ameliorate the clinical severity of multiple sclerosis (MS).
Purpose of the Study:
- To evaluate the synergistic effects of combined MSCs-IFN-β and minocycline treatment on EAE.
- To investigate the mechanisms underlying the combined treatment's efficacy in EAE.
Main Methods:
- Treatment of EAE mice with MSCs-IFN-β, minocycline, or a combination thereof.
- Assessment of clinical severity and histological/molecular markers of disease.
Main Results:
- The combined treatment significantly alleviated EAE clinical severity compared to individual treatments.
- This alleviation was associated with maintained blood-spinal cord barrier integrity.
- Mechanisms involved inhibition of microvascular disruption, matrix metalloproteinases, and neuroinflammation, alongside enhanced immunomodulatory effects.
Conclusions:
- Combined MSCs-IFN-β and minocycline treatment offers a potent therapeutic strategy for EAE.
- This combination holds significant potential for improving functional recovery in multiple sclerosis patients.
More Related Videos
09:38Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
08:47Induction of Experimental Autoimmune Encephalomyelitis in Mice and Evaluation of the Disease-dependent Distribution of Immune Cells in Various Tissues
Published on: May 8, 2016